Beyond Air® Preannounces Preliminary Revenue for the Quarter Ended September 30, 2026
Beyond Air preannounced preliminary unaudited revenue of approximately $2.3 million for the quarter ended September 30, 2026 — its highest quarterly revenue to date, up roughly 30% sequentially and 27% year over year. Growth reflects continued hospital adoption of the first-generation LungFit PH nitric oxide delivery system, while the second-generation system remains under FDA review via a PMA supplement. The company reaffirmed revenue guidance of $8 million for CY2026 and $16-$18 million for CY2027, with the higher 2027 figure contingent on FDA approval of the second-generation system.
Key figures
- Revenue
- $2.3 million
- Guidance
- Reaffirmed $8 million CY2026 revenue (excludes second-generation system) and $16-$18 million CY2027 revenue (includes second-generation, pending FDA approval)
- Revenue Yoy
- 27%
- Period
- quarter ended September 30, 2026
- Full results date
- November 2026
- Sequential growth
- approximately 30% vs quarter ended June 30, 2026
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.